Shots:

• Alpine to receive $60M up front- ~$805M as option exercise fee- development- regulatory and commercial milestones along with royalties on net sales of ALPN-101
• AbbVie to get an option to exclusively license ALPN-101- following exercising the option- AbbVie will conduct all future clinical development- manufacturing- and commercialization activities for ALPN-101
• During the option period- Alpine will conduct a P-II study in systemic lupus erythematosus. ALPN-101 is a first in class dual CD28/ICOS co-stimulation antagonist which demonstrated efficacy in multiple preclinical disease models- superior to blockade of either pathway alone

Click here to read full press release/ article 

Ref: Alpine | Image: AbbVie